<DOC>
	<DOCNO>NCT01260948</DOCNO>
	<brief_summary>This study investigate relative bioavailability ( rate extend absorption ) Donepezil Hydrochloride Orally Disintegrating Tablets , 10 mg Teva Pharmaceuticals , USA AriceptÂ® Orally Disintegrating Tablets , Manufactured Marketed Eisai Inc. , follow single oral dose ( 1 x 10 mg orally disintegrate tablet ) healthy adult subject administer non-fasting condition .</brief_summary>
	<brief_title>10 mg Donepezil Hydrochloride Orally Disintegrating Tablets Under Non-Fasting Conditions</brief_title>
	<detailed_description />
	<mesh_term>Donepezil</mesh_term>
	<criteria>Screening Demographics : All volunteer select study healthy men woman 18 year age old time dose . The weight range exceed + 20 % height weight per Desirable Weights Adults 1983 Metropolitan Height Weight Table . Screening Procedures : Each volunteer complete screening process within 28 day prior Period I dose . Consent document screen evaluation HIV antibody determination review , discuss , sign potential participant full implementation screening procedure . If female : childbearing potential , practice acceptable method birth control duration study judge investigator ( ) ; postmenopausal least 1 year ; surgically sterile . Volunteers recent history drug alcohol addiction abuse . Volunteers presence clinically significant disorder involve cardiovascular , respiratory , renal , gastrointestinal , immunologic , hematologic , endocrine , neurologic system ( ) psychiatric disease ( determined clinical investigator ) . Volunteers whose clinical laboratory test value outside accept reference range confirm reexamination deem clinically significant . Volunteers demonstrate reactive screen Hepatitis B surface antigen , hepatitis C antibody , HIV antibody . Volunteers demonstrate positive drug abuse screen screen study . Female volunteer demonstrate positive pregnancy screen . Female volunteer currently breastfeed . Volunteers history allergic response ( ) donepezil relate drug . Volunteers history clinically significant allergy include drug allergy . Volunteers clinically significant illness 4 week prior Period I dose ( determined clinical investigator ) . Volunteers currently use tobacco product . Volunteers take drug know induce inhibit hepatic drug metabolism 28 day prior Period I dose . Volunteers report donate great 150 mL blood within 28 day prior Period I dose . Volunteers donate plasma within 14 day Period I dose . Volunteers report receive investigational drug within 28 day prior Period I dose . Volunteers report take systemic prescription medication 14 day prior Period I dose . Female volunteer report use oral contraceptive injectable contraceptive .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2011</verification_date>
	<keyword>Bioequivalence</keyword>
	<keyword>Healthy Subjects</keyword>
</DOC>